NW BIO MAKING A JOINT POSTER PRESENTATION ON ITS DCVAX-DIRECT TRIAL AT THE 29TH ANNUAL SITC MEETING

News provided by

Nov 07, 2014, 09:15 ET

BETHESDA, Md., Nov. 7, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it will be making a joint poster presentation relating to its DCVax-Direct Phase I/II Trial for inoperable solid tumor cancers at the 29^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

The SITC conference is the largest immuno-oncology conference worldwide. NW Bio's poster presentation will take place from 12:30 pm to 2:00 pm, and again from 6:10 pm to 7:30 pm today, Friday, November 7, 2014 in the Prince Georges Exhibit Hall C at the Gaylord National Hotel and Convention Center at National Harbor, Maryland.

The title of the Poster Presentation is: Activated Autologous Dendritic Cells Injected Intratumorally Are Able To Overcome Local and Systemic Immune Suppression Imposed By The Tumor And Its Microenvironment. The 12 co-authors of the joint Poster, in addition to Dr. Marnix Bosch of NW Bio, include 9 physicians from the M.D. Anderson Cancer Center, two from the University of Texas Health, and one from U.C.L.A. The Poster will be placed on the Company's website following presentation at the SITC conference.

The presentation focuses on a couple of case studies demonstrating a range of clinical effects of the direct injection of a patient's partially activated dendritic cells into inoperable tumors to generate both local and generalized anti-tumor immune responses, as seen in patients in the Phase I stage of the DCVax-Direct trial.

The case studies to be reviewed include a new case study of an advanced ovarian cancer patient with metastatic lymph nodes and an ongoing case study of a sarcoma patient with a very large primary tumor and multiple metastatic tumors in the lungs. These diverse cancers and patients illustrate both local and systemic effects being seen in the DCVax-Direct clinical trial: tumor cell death in the injected tumors, as well as shrinkage of some of the metastatic tumors and stabilization of others.

Dr. Marnix Bosch, Chief Technical Officer of NW Bio and senior author of the poster, commented, "We continue to be gratified by the enthusiasm of our longstanding collaborators and their dedication to making this new DCVax-Direct treatment a success. The case studies presented in this poster are just a few of the numerous cases in which we are seeing both local and systemic effects of DCVax-Direct. We are looking forward to building upon this learning as we initiate the Phase II stage of this trial in the near future, while we also continue gathering data from the patients continuing to be treated in the Phase I portion of the trial."

In addition to the joint poster presentation, NW Bio will have an Exhibit Booth in the Exhibit Hall at the SITC meeting. SITC attendees are encouraged to visit the Booth to learn more about NW Bio's multiple international programs and products for operable and inoperable solid tumor cancers.

About The SITC 29^th Annual Meeting

The SITC Annual Meeting is the leading cancer immunotherapy conference, hosted in National Harbor, Maryland. Known as the premier destination for scientific exchange, education and networking in the cancer immunotherapy community, attendees will be a part of more than 1,100 basic, clinical and translational scientists from academia, government and industry, along with other top medical professionals from around the world, all dedicated to improving cancer patient outcomes through cancer immunotherapy.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers, with a primary efficacy endpoint of tumor regression. It has completed enrollment in the Phase I portion of the trial. The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer. The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania. In Germany, the Company has also received approval of a 5-year Hospital Exemption for the treatment of all gliomas (brain cancer) patients outside the clinical trial.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Logo - http://photos.prnewswire.com/prnh/20110329/SF73084LOGO

SOURCE Northwest Biotherapeutics